Generation and Characterization of Iduronidase-Cleavable ADCs
Bioconjugate Chemistry · 2023
DOI: 10.1021/acs.bioconjchem.3c00363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2023. Verfasst von Sebastian Jäger und 11 weiteren Autor:innen. Beteiligte Einrichtung: Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany. Hauptthemen laut MEDLINE: Immunoconjugates, Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
A crucial design feature for the therapeutic success of antibody-drug conjugates (ADCs) is the linker that connects the antibody with the drug. Linkers must be stable in circulation and efficiently release the drug inside the target cell, thereby having a fundamental impact on ADC pharmacokinetics and efficacy. The variety of enzymatically cleavable linkers applied in ADCs is limited, and some are believed to be associated with unwanted side effects due to the expression of cleavage-mediating enzymes in nonmalignant cells. Based on a bioinformatic screen of lysosomal enzymes, we identified α-l-iduronidase (IduA) as an interesting candidate for ADC linker cleavage because of its low expression in normal tissues and its overexpression in several tumor types. In the present study, we report a novel IduA-cleavable ADC linker using exatecan and duocarmycin as payloads. We showed the functionality of our linker system in cleavage assays using recombinant IduA or cell lysates and compared it to established ADC linkers. Subsequently, we coupled iduronide-exatecan via interchain cysteines or iduronide-duocarmycin via microbial transglutaminase (mTG) to an anti-CEACAM5 (aCEA5) antibody. The generated iduronide-exatecan ADC showed high serum stability and similar target-dependent tumor cell killing in the subnanomolar range but reduced toxicity on nonmalignant cells compared to an analogous cathepsin B-activatable valine-citrulline-exatecan ADC. Finally, in vivo antitumor activity could be demonstrated for an IduA-cleavable duocarmycin ADC. The presented results emphasize the potential of iduronide linkers for ADC development and represent a tool for further balancing out tumor selectivity and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany.
- Bioorganic Chemistry, University of Bayreuth, Universitätsstraße 30, 95447 Bayreuth, Germany.
ORCID-Profile: Sebastian Jäger, Janike Sensbach
Zitieren
APA
Jäger, S., Könning, D., Rasche, N., Hart, F., Sensbach, J., Krug, C., Raab-Westphal, S., Richter, K., Unverzagt, C., Hecht, S., Anderl, J., & Schröter, C. (2023). Generation and Characterization of Iduronidase-Cleavable ADCs. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.3c00363
Vancouver
Jäger S, Könning D, Rasche N, Hart F, Sensbach J, Krug C, et al. Generation and Characterization of Iduronidase-Cleavable ADCs. Bioconjugate Chemistry. 2023. doi:10.1021/acs.bioconjchem.3c00363
BibTeX
@article{Jger2023,
author = {Jäger, Sebastian and Könning, Doreen and Rasche, Nicolas and Hart, Felix and Sensbach, Janike and Krug, Carina and Raab-Westphal, Sabine and Richter, Konstantin and Unverzagt, Carlo and Hecht, Stefan and Anderl, Jan and Schröter, Christian},
title = {Generation and Characterization of Iduronidase-Cleavable ADCs},
journal = {Bioconjugate Chemistry},
year = {2023},
doi = {10.1021/acs.bioconjchem.3c00363}
}
EUVIMED